Published in J Infect Dis on October 07, 2005
Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis (2006) 4.21
In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis (2009) 2.80
Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother (2006) 2.74
In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother (2009) 2.36
Transporters involved in resistance to antimalarial drugs. Trends Pharmacol Sci (2006) 2.09
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob Agents Chemother (2010) 1.83
Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance. PLoS One (2011) 1.73
Plasmodium falciparum pfmdr1 amplification, mefloquine resistance, and parasite fitness. Antimicrob Agents Chemother (2009) 1.72
Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-negative women: a multicentre randomized controlled trial. PLoS Med (2014) 1.64
Phenotypic and genotypic analysis of in vitro-selected artemisinin-resistant progeny of Plasmodium falciparum. Antimicrob Agents Chemother (2011) 1.57
Molecular epidemiology of malaria. Clin Microbiol Rev (2007) 1.53
Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance. Trends Mol Med (2006) 1.42
Chloroquine susceptibility and reversibility in a Plasmodium falciparum genetic cross. Mol Microbiol (2010) 1.42
Gene amplification of the multidrug resistance 1 gene of Plasmodium vivax isolates from Thailand, Laos, and Myanmar. Antimicrob Agents Chemother (2008) 1.39
Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine. Antimicrob Agents Chemother (2011) 1.32
Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-infected women receiving cotrimoxazole prophylaxis: a multicenter randomized placebo-controlled trial. PLoS Med (2014) 1.27
pfmdr1 amplification associated with clinical resistance to mefloquine in West Africa: implications for efficacy of artemisinin combination therapies. J Clin Microbiol (2010) 1.05
No variation in the prevalence of point mutations in the Pfcrt and Pfmdr1 genes in isolates from Gabonese patients with uncomplicated or severe Plasmodium falciparum malaria. Parasitol Res (2006) 1.05
Artemether resistance in vitro is linked to mutations in PfATP6 that also interact with mutations in PfMDR1 in travellers returning with Plasmodium falciparum infections. Malar J (2012) 1.03
Plasmodium falciparum isolates with increased pfmdr1 copy number circulate in West Africa. Antimicrob Agents Chemother (2010) 1.02
Parasites bearing a single copy of the multi-drug resistance gene (pfmdr-1) with wild-type SNPs predominate amongst Plasmodium falciparum isolates from Malawi. Acta Trop (2009) 1.00
Antimalarial activity of a synthetic endoperoxide (RBx-11160/OZ277) against Plasmodium falciparum isolates from Gabon. Antimicrob Agents Chemother (2006) 0.94
No pfmdr1 amplifications in samples from Guinea-Bissau and Liberia collected between 1981 and 2004. J Infect Dis (2006) 0.93
Fitness consequences of Plasmodium falciparum pfmdr1 polymorphisms inferred from ex vivo culture of Ugandan parasites. Antimicrob Agents Chemother (2013) 0.88
Automated red blood cell exchange as an adjunctive treatment for severe Plasmodium falciparum malaria at the Vienna General Hospital in Austria: a retrospective cohort study. Malar J (2012) 0.85
Analysis of major genome loci underlying artemisinin resistance and pfmdr1 copy number in pre- and post-ACTs in western Kenya. Sci Rep (2015) 0.83
Pharmacokinetics of ferroquine, a novel 4-aminoquinoline, in asymptomatic carriers of Plasmodium falciparum infections. Antimicrob Agents Chemother (2012) 0.83
Temporal trends in prevalence of Plasmodium falciparum molecular markers selected for by artemether-lumefantrine treatment in pre-ACT and post-ACT parasites in western Kenya. Int J Parasitol Drugs Drug Resist (2015) 0.80
Updates on artemisinin: an insight to mode of actions and strategies for enhanced global production. Protoplasma (2015) 0.77
Molecular surveillance of Plasmodium falciparum resistance to artemisinin-based combination therapies in the Democratic Republic of Congo. PLoS One (2017) 0.75
Plasmodium falciparum genetic diversity of continental Equatorial Guinea before and after introduction of Artemisinin based Combination Therapy. Antimicrob Agents Chemother (2016) 0.75
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med (2011) 10.79
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med (2012) 6.64
The trypanosomiases. Lancet (2003) 5.96
Allergy, parasites, and the hygiene hypothesis. Science (2002) 5.01
Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis (2006) 4.21
Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis (2006) 4.14
Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infect Dis (2008) 4.07
Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J (2004) 3.80
Genome variation and evolution of the malaria parasite Plasmodium falciparum. Nat Genet (2006) 3.68
Antimalarial combinations. Lancet (2004) 3.54
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. Lancet Infect Dis (2013) 3.46
A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. Nat Struct Mol Biol (2005) 3.18
Recurrent gene amplification and soft selective sweeps during evolution of multidrug resistance in malaria parasites. Mol Biol Evol (2006) 3.01
Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet (2006) 2.96
Short report: Piloting paperless data entry for clinical research in Africa. Am J Trop Med Hyg (2005) 2.85
Placental malaria increases malaria risk in the first 30 months of life. Clin Infect Dis (2008) 2.69
Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis (2011) 2.54
Standardized data collection for multi-center clinical studies of severe malaria in African children: establishing the SMAC network. Trans R Soc Trop Med Hyg (2006) 2.52
Severe falciparum malaria in Gabonese children: clinical and laboratory features. Malar J (2005) 2.35
Likely health outcomes for untreated acute febrile illness in the tropics in decision and economic models; a Delphi survey. PLoS One (2011) 2.24
A novel and accurate diagnostic test for human African trypanosomiasis. Lancet (2004) 2.22
The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop Med Int Health (2007) 2.17
Fosmidomycin for malaria. Lancet (2002) 2.03
High prevalence of asymptomatic Plasmodium falciparum infection in Gabonese adults. Am J Trop Med Hyg (2007) 1.99
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial. J Infect Dis (2007) 1.99
Detection of arsenical drug resistance in Trypanosoma brucei with a simple fluorescence test. Lancet (2005) 1.94
A prospective comparison of malaria with other severe diseases in African children: prognosis and optimization of management. Clin Infect Dis (2003) 1.93
Microscopic and sub-microscopic Plasmodium falciparum infection, but not inflammation caused by infection, is associated with low birth weight. Am J Trop Med Hyg (2006) 1.88
Long-term treatment of intestinal helminths increases mite skin-test reactivity in Gabonese schoolchildren. J Infect Dis (2004) 1.85
Impact of the hepatitis B virus genotype and genotype mixtures on the course of liver disease in Vietnam. Hepatology (2006) 1.82
Human African trypanosomiasis. BMJ (2002) 1.79
Severe malaria - a case of fatal Plasmodium knowlesi infection with post-mortem findings: a case report. Malar J (2010) 1.72
Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis (2008) 1.70
Influenza in Africa. PLoS Med (2009) 1.68
Import and spread of Panton-Valentine Leukocidin-positive Staphylococcus aureus through nasal carriage and skin infections in travelers returning from the tropics and subtropics. Clin Infect Dis (2011) 1.67
Increased specific T cell cytokine responses in patients with active pulmonary tuberculosis from Central Africa. Microbes Infect (2005) 1.63
Depressed natural killer cell cytotoxicity against Plasmodium falciparum-infected erythrocytes during first pregnancies. Clin Infect Dis (2004) 1.61
Management of imported malaria in Europe. Malar J (2012) 1.60
Intramuscular bioavailability and clinical efficacy of artesunate in gabonese children with severe malaria. Antimicrob Agents Chemother (2002) 1.59
Increased prevalence of intestinal helminth infection during pregnancy in a Sub-Saharan African community. Wien Klin Wochenschr (2007) 1.58
Does treatment of intestinal helminth infections influence malaria? Background and methodology of a longitudinal study of clinical, parasitological and immunological parameters in Nangapanda, Flores, Indonesia (ImmunoSPIN Study). BMC Infect Dis (2010) 1.57
Impact of increasing consultation fees on malaria in Africa. Wien Klin Wochenschr (2004) 1.56
Cerebrospinal fluid neopterin as marker of the meningo-encephalitic stage of Trypanosoma brucei gambiense sleeping sickness. PLoS One (2012) 1.55
History and perspectives of medical research at the Albert Schweitzer Hospital in Lambaréné, Gabon. Wien Klin Wochenschr (2007) 1.52
Assessment of volume depletion in children with malaria. PLoS Med (2004) 1.51
Matrix metalloproteinases and their tissue inhibitors (TIMPs) in Plasmodium falciparum malaria: serum levels of TIMP-1 are associated with disease severity. J Infect Dis (2008) 1.51
Intrahost selection of Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand. J Infect Dis (2006) 1.49
Socio-economic status is inversely related to bed net use in Gabon. Malar J (2008) 1.46
Adolescence as risk factor for adverse pregnancy outcome in Central Africa--a cross-sectional study. PLoS One (2010) 1.43
Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. PLoS Med (2006) 1.42
Effectiveness of rifaximin in prevention of diarrhoea in individuals travelling to south and southeast Asia: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect Dis (2013) 1.41
Evidence of decline of malaria in the general hospital of Libreville, Gabon from 2000 to 2008. Malar J (2009) 1.40
Reduced cord blood immune effector-cell responsiveness mediated by CD4+ cells induced in utero as a consequence of placental Plasmodium falciparum infection. J Infect Dis (2005) 1.40
Plasmodium falciparum activates endogenous Cl(-) channels of human erythrocytes by membrane oxidation. EMBO J (2002) 1.40
Validation of the hexose transporter of Plasmodium falciparum as a novel drug target. Proc Natl Acad Sci U S A (2003) 1.38
Differential regulation of beta-chemokines in children with Plasmodium falciparum malaria. Infect Immun (2005) 1.37
Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob Agents Chemother (2002) 1.36
Elevated nitric oxide production in children with malarial anemia: hemozoin-induced nitric oxide synthase type 2 transcripts and nitric oxide in blood mononuclear cells. Infect Immun (2004) 1.35
Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria. Antimicrob Agents Chemother (2006) 1.35
Acute respiratory distress syndrome in Plasmodium vivax malaria: case report and review of the literature. Trans R Soc Trop Med Hyg (2007) 1.35
Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children. J Infect Dis (2004) 1.35
Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. J Infect Dis (2004) 1.34
Malaria in pregnancy before and after the implementation of a national IPTp program in Gabon. Am J Trop Med Hyg (2007) 1.34
A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS One (2009) 1.31
The prognostic value of measures of acid/base balance in pediatric falciparum malaria, compared with other clinical and laboratory parameters. Clin Infect Dis (2005) 1.30
Submicroscopic Plasmodium falciparum infections and multiplicity of infection in matched peripheral, placental and umbilical cord blood samples from Gabonese women. Trop Med Int Health (2004) 1.29
Recognition of variant Rifin antigens by human antibodies induced during natural Plasmodium falciparum infections. Infect Immun (2002) 1.27
Comprehensive study of proteasome inhibitors against Plasmodium falciparum laboratory strains and field isolates from Gabon. Malar J (2008) 1.27
Community response to intermittent preventive treatment of malaria in infants (IPTi) delivered through the expanded programme of immunization in five African settings. Malar J (2009) 1.26
Waking up to sleeping sickness. Trends Parasitol (2003) 1.25
Mechanism of antimalarial action of the synthetic trioxolane RBX11160 (OZ277). Antimicrob Agents Chemother (2006) 1.25
Life cycle studies of the hexose transporter of Plasmodium species and genetic validation of their essentiality. Mol Microbiol (2009) 1.25
Artesunate--amodiaquine combination therapy for falciparum malaria in young Gabonese children. Malar J (2007) 1.23
The sickle cell trait is associated with enhanced immunoglobulin G antibody responses to Plasmodium falciparum variant surface antigens. J Infect Dis (2005) 1.23
Aquaporin water channels and brain edema. Mt Sinai J Med (2002) 1.22
The cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan Africa. PLoS One (2010) 1.22
Responses to Toll-like receptor ligands in children living in areas where schistosome infections are endemic. J Infect Dis (2004) 1.21
Artemisinins inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense in vitro growth. Antimicrob Agents Chemother (2007) 1.21
Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J Infect Dis (2010) 1.21
Epidemiology of parasitic co-infections during pregnancy in Lambaréné, Gabon. Trop Med Int Health (2010) 1.20